Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tbingen, Germany.

CureVac N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2025 AND PROVIDES BUSINESS UPDATES ENTERED INTO A DEFINITIVE PURCHASE AGREEMENT PURSUANT TO WHICH BIONTECH INTENDS TO ACQUIRE ALL SHARES OF CUREVAC, UNITING TWO HIGHLY COMPLEMENTARY GERMAN COMPANIES TO BRING TRANSFORMATIVE MRNA-BASED TREATMENTS TO PATIENTS GLOBALLY ENTERED INTO AGREEMENTS TO RESOLVE AND DISMISS ALL PENDING PATENT LITIGATION IN THE U.S. WITH PFIZER/BIONTECH RELATED TO MRNA-BASED COVID-19 VACCINES AND TO SET A FRAMEWORK FOR RESOLVING RELATED ONGOING PATENT DISPUTES OUTSIDE THE U.S. UPON CLOSING OF BIONTECH'S ACQUISITION OF CUREVAC RECEIVED CLINICAL TRIAL APPLICATION (CTA) CLEARANCE FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CVHNLC, A PROPRIETARY OFF-THE-SHELF CANCER IMMUNOTHERAPY CANDIDATE TARGETING SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) CVGBM GLIOBLASTOMADATA FROM PART B OF PHASE 1 REMAIN ON TRACK FOR H2 2025 STRONG CASH AND CASH EQUIVALENTS POSITION OF 392.7 MILLION AS OF JUNE 30, 2025; EXPECTED CASH RUNWAY INTO 2028 TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / AUGUST 15, 2025 / CUREVAC N.V. (NASDAQ:CVAC), A PIONEERING MULTINATIONAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RNA (MRNA), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2025 AND PROVIDED A BUSINESS UPDATE.

CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2025 AND PROVIDES BUSINESS UPDATES

TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / JUNE 24, 2025 / CUREVAC N.V. (NASDAQ:CVAC), A PIONEERING MULTINATIONAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RNA (MRNA), TODAY ANNOUNCED THE VOTING RESULTS OF THE COMPANY'S ANNUAL GENERAL MEETING.

CUREVAC ANNOUNCES VOTING RESULTS OF GENERAL MEETING

U.S. FDA CLEARS LUNG CANCER IND FOR CVHNLC, A PROPRIETARY OFF-THE-SHELF CANDIDATE TARGETING SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNCLC), WITH CLINICAL STUDY EXPECTED TO BEGIN H2 2025; CLINICAL TRIAL APPLICATION FILED IN EUROPE WITH DECISION EXPECTED IN Q2 2025 GLIOBLASTOMA STUDY FULLY ENROLLED WITH PART B OF PHASE 1 CVGBM TRIAL COMPLETING ENROLMENT IN Q1 2025; GO/NO-GO DECISION ON MOVING TO PHASE 2 PLANNED FOR H2 2025 FIRST URINARY TRACT INFECTION VACCINE MOVING FORWARD WITH U.S. IND FILING PLANNED FOR H2 2025 CORE MRNA PATENTS UPHELD AS EUROPEAN PATENT OFFICE CONFIRMED VALIDITY OF TWO KEY PATENTS IN AMENDED FORM; INFRINGEMENT HEARING AGAINST BIONTECH/PFIZER BEFORE THE REGIONAL COURT DSSELDORF SET FOR JULY 1, 2025 STRONG CASH AND CASH EQUIVALENTS POSITION OF 438.3 MILLION AS OF MARCH 31, 2025; REAFFIRMING EXPECTED CASH RUNWAY INTO 2028 TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / MAY 20, 2025 / CUREVAC N.V. (NASDAQ:CVAC), A PIONEERING MULTINATIONAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RNA (MRNA), TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025 AND PROVIDED A BUSINESS UPDATE.

CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025 AND PROVIDES BUSINESS UPDATES

EUROPEAN PATENT OFFICE LARGELY DISMISSES OPPOSITION FILED BY BIONTECH SE, PFIZER INC., AND OTHERS IN DECEMBER 2023 CHALLENGING VALIDITY OF EP 4 023 755 B1 AND MAINTAINS THE PATENT SUBJECT TO AMENDMENTS TO SPECIFIC PATENT CLAIMS A HEARING ON INFRINGEMENT OF EP 4 023 755 B1 WHICH WILL ALSO INCLUDE EP 3 708 668 B1, THE VALIDITY OF WHICH WAS CONFIRMED IN AMENDED FORM IN MARCH 2025, IS SCHEDULED FOR JULY 1, 2025, BEFORE THE REGIONAL COURT DSSELDORF, GERMANY TUBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / MAY 15, 2025 / CUREVAC N.V. (NASDAQ:CVAC) ("CUREVAC"), A GLOBAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RIBONUCLEIC ACID ("MRNA"), TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE (EPO) HAS CONFIRMED THE VALIDITY OF CUREVAC'S EUROPEAN PATENT EP 4 023 755 B1 SUBJECT TO AMENDMENTS TO SPECIFY THE SCOPE OF PROTECTION.

CUREVAC RECEIVES ADDITIONAL POSITIVE VALIDITY DECISION FROM EUROPEAN PATENT OFFICE IN ONGOING LITIGATION AGAINST BIONTECH SE

STRATEGIC MILESTONE ACHIEVEMENT AND INCREASED FINANCIAL DISCIPLINE UNDERSCORE YEAR OF CORPORATE TRANSFORMATION COMPLETED ENROLLMENT OF PART B OF PHASE 1 GLIOBLASTOMA STUDY WITH INVESTIGATIONAL PRECISION IMMUNOTHERAPY CVGBM; PART B FIRST DATA READOUT ANTICIPATED IN H2 2025 FILED IND AND CTA SUBMISSIONS FOR PHASE 1 STUDY WITH PROPRIETARY OFF-THE-SHELF PROGRAM IN SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC) RECEIVED FDA CLEARANCE TO PROCEED WITH SQNSCLC PHASE 1 STUDY; EXPECTED TO START IN H2 2025 INVOICED 10 MILLION MILESTONE PAYMENT FOLLOWING INITIATION OF PHASE 1 OF THE COMBINED PHASE 1/2 STUDY OF A SEASONAL INFLUENZA/COVID-19 COMBINATION VACCINE; PROGRAM FULLY LICENSED TO GSK RECEIVED POSITIVE VALIDITY DECISION FOR PATENT EP 3 708 668 B1 IN AMENDED FORM FROM EUROPEAN PATENT OFFICE (EPO) IN INTER PARTES PROCEEDINGS AGAINST BIONTECH SE JURY TRIAL IN U.S. LITIGATION POSTPONED TO SEPTEMBER 8, 2025, BY THE DISTRICT COURT OF THE EASTERN DISTRICT OF VIRGINIA CASH AND CASH EQUIVALENTS POSITION OF 481.7 MILLION AS OF DECEMBER 31, 2024; REAFFIRMING EXPECTED CASH RUNWAY INTO 2028 CUREVAC TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 9 A.M. EST / 3 P.M.

CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2024 AND PROVIDES BUSINESS UPDATE

TBINGEN, DE / ACCESS NEWSWIRE / APRIL 8, 2025 / CUREVAC N.V. (NASDAQ:CVAC) ("CUREVAC"), A GLOBAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RIBONUCLEIC ACID ("MRNA"), WILL REPORT FINANCIAL RESULTS, AND PROVIDE BUSINESS UPDATES FOR THE FOURTH QUARTER AND FULL-YEAR 2024 ON THURSDAY, APRIL 10, 2025.

CUREVAC TO REPORT FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATE ON APRIL 10, 2025

SIGNIFICANT REGULATORY MILESTONE: U.S. FDA CLEARED IND APPLICATION FOR CVHNLC, CUREVAC'S INVESTIGATIONAL THERAPY TARGETING SQUAMOUS NON-SMALL CELL LUNG CANCER PROPRIETARY EPITOPES: CVHNLC ENCODES NOVEL TUMOR EPITOPES IDENTIFIED THROUGH PROPRIETARY WHOLE GENOME-BASED DISCOVERY PLATFORM ENHANCED COMBINATION THERAPY: CVHNLC TO BE TESTED IN COMBINATION WITH PEMBROLIZUMAB, AIMING TO AMPLIFY TARGETED ANTI-TUMOR IMMUNE RESPONSES CLINICAL PROGRESS: PATIENT TREATMENT ANTICIPATED TO START IN THE SECOND HALF OF 2025 PIPELINE ADVANCEMENT: IND CLEARANCE HIGHLIGHTS CUREVAC'S CONTINUED ONCOLOGY PIPELINE GROWTH, WITH MORE CANDIDATES PLANNED TO ENTER THE CLINIC IN 2026 TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / APRIL 7, 2025 / CUREVAC N.V. (NASDAQ:CVAC) ("CUREVAC"), A GLOBAL BIOTECH COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RIBONUCLEIC ACID ("MRNA"), TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS CLEARED ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR A PHASE 1 CLINICAL STUDY OF CVHNLC IN PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER (SQNSCLC).

CUREVAC RECEIVES U.S. FDA IND CLEARANCE TO INITIATE PHASE 1 CLINICAL TRIAL FOR NOVEL MRNA-BASED PRECISION IMMUNOTHERAPY IN SQUAMOUS NON-SMALL CELL LUNG CANCER

EUROPEAN PATENT OFFICE LARGELY DISMISSES OPPOSITION FILED BY BIONTECH SE IN APRIL 2023 CHALLENGING VALIDITY OF EP 3 708 668 B1 AND MAINTAINS THE PATENT IN AMENDED FORM A HEARING ON INFRINGEMENT OF EP 3 708 668 B1 IS SCHEDULED FOR JULY 1, 2025, BEFORE THE REGIONAL COURT DSSELDORF CONFIRMING VALIDITY OF PATENT IN ITS AMENDED FORM MARKS MAJOR MILESTONE IN BROADER PATENT LITIGATION IN GERMANY, RECOGNIZING CUREVAC'S PIONEERING MRNA INNOVATION TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / MARCH 27, 2025 / CUREVAC N.V. (NASDAQ:CVAC) ("CUREVAC"), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RIBONUCLEIC ACID ("MRNA"), TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE (EPO) HAS CONFIRMED THE VALIDITY OF CUREVAC'S EUROPEAN PATENT EP 3 708 668 B1 SUBJECT TO AMENDMENTS TO SPECIFY THE SCOPE OF PROTECTION.

CUREVAC RECEIVES POSITIVE VALIDITY DECISION FROM EUROPEAN PATENT OFFICE IN LITIGATION AGAINST BIONTECH SE

CUREVAC AMONG GLOBAL TOP 100 MOST FAST-PACED INNOVATORS FOR THIRD CONSECUTIVE YEAR IN ACKNOWLEDGMENT OF ITS INNOVATIVE STRENGTH AND EXTENSIVE INTELLECTUAL PROPERTY PORTFOLIO THE COMPANY HOLDS ONE OF THE BROADEST INTELLECTUAL PROPERTY PORTFOLIOS IN MRNA TECHNOLOGY TBINGEN, GERMANY AND BOSTON, MA / ACCESS NEWSWIRE / FEBRUARY 18, 2025 / CUREVAC N.V. (NASDAQ:CVAC), A GLOBAL BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF TRANSFORMATIVE MEDICINES BASED ON MESSENGER RIBONUCLEIC ACID ("MRNA"), TODAY ANNOUNCED ITS RECOGNITION AS A TOP 100 GLOBAL INNOVATOR IN THE INNOVATION MOMENTUM 2025 REPORT BY LEXISNEXIS.

CUREVAC EARNS REPEAT RECOGNITION BY LEXISNEXIS(R) AS ONE OF THE WORLD'S TOP INNOVATORS

STRENGTHENED CASH, STRATEGIC REFOCUS AND PIPELINE PROGRESS DEFINE TRANSFORMATIVE QUARTER 400 MILLION UPFRONT PAYMENT FROM RESTRUCTURED GSK COLLABORATION REFLECTED IN FINANCIALS, CASH POSITION INCREASED TO 551 MILLION; EXPECTED CASH RUNWAY RE-AFFIRMED INTO 2028 CVGBM PHASE 1 GLIOBLASTOMA STUDY SHOWED 77% OF PATIENTS WITH ANTIGEN-SPECIFIC T-CELL RESPONSES; DATA PRESENTED AT ESMO, SITC AND SNO NEW OFF-THE-SHELF PROGRAM FOR SQUAMOUS NON-SMALL CELL LUNG CANCER STARTED, EXPECTED TO ENTER PHASE 1 IN H2 2025 NEW PRECLINICAL PROPHYLACTIC VACCINE PROGRAM FOR URINARY TRACT INFECTIONS INITIATED, SUPPORTED BY POSITIVE PRECLINICAL DATA VERSUS PROTEIN-BASED VACCINES POSITIVE PHASE 2 DATA FROM SEASONAL INFLUENZA PROGRAM LICENSED TO GSK DEMONSTRATED STRONG IMMUNE RESPONSES AGAINST CHALLENGING INFLUENZA B AS WELL AS A STRAINS; PROGRAM PROGRESSING TO PHASE 3, WHICH WILL BE ASSOCIATED WITH SIGNIFICANT MILESTONE PAYMENT CORPORATE REDESIGN ON TRACK WITH 30% WORKFORCE REDUCTION, EXPECTED TO YIELD SIGNIFICANT ANNUAL COST SAVINGS FROM 2025 ONWARDS AND INCREASE OPERATIONAL AGILITY APPOINTMENT OF SEASONED INDUSTRY EXECUTIVE AXEL MALKOMES AS NEW CFO EFFECTIVE NOVEMBER 11, ENHANCING FINANCIAL LEADERSHIP AND STRATEGIC EXECUTION CUREVAC TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 9 A.M. EST / 3 P.M.

CureVac N.V.

CVAC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CureVac N.V.

CVAC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CVAC